Angiotensin II type 1 receptor antagonists lower blood pressure and reduce mortality in animal models of hypertension, exhibiting beneficial effects beyond blood pressure reduction.
Do ARBs have beneficial effects on vascular, cardiac, metabolic, and renal disease in animal models beyond blood pressure lowering?
ARBs demonstrate pleiotropic beneficial effects on cardiovascular, renal, and metabolic parameters in animal models that extend beyond their blood pressure-lowering capabilities.
We have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin-angiotensin system; blood pressure lowering even persists for a considerable time after discontinuation of treatment. This translates into a reduced mortality, particularly in models exhibiting marked hypertension. The retrieved data on vascular, cardiac and renal function and morphology as well as on glucose and lipid metabolism are discussed to address three main questions: 1. Can ARB effects on blood vessels, heart, kidney and metabolic function be explained by blood pressure lowering alone or are they additionally directly related to blockade of the renin-angiotensin system? 2. Are they shared by other inhibitors of the renin-angiotensin system, e.g. angiotensin converting enzyme inhibitors? 3. Are some effects specific for one or more compounds within the ARB class? Taken together these data profile ARBs as a drug class with unique properties that have beneficial effects far beyond those on blood pressure reduction and, in some cases distinct from those of angiotensin converting enzyme inhibitors. The clinical relevance of angiotensin receptor-independent effects of some ARBs remains to be determined.
Michel et al. (Fri,) conducted a review in Hypertension, atherosclerosis, cardiac, metabolic and renal disease. Angiotensin II type 1 receptor antagonists (ARBs) vs. Angiotensin converting enzyme inhibitors was evaluated. Angiotensin II type 1 receptor antagonists lower blood pressure and reduce mortality in animal models of hypertension, exhibiting beneficial effects beyond blood pressure reduction.